regdanvimab (Regkirona- CT-P59-Celltrion) - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.50 [0.05, 5.54]< 10%1 study (1/-)71.2 %NAnot evaluable crucial-
hospitalization or death 0.33 [0.20, 0.53]< 10%2 studies (2/-)100.0 %NAnot evaluable crucial-
clinical improvement (time to event analysis only) 1.50 [1.30, 1.74]> 10%1 study (1/-)100.0 %NAnot evaluable important-
Recovery (time to event analysis only) 1.50 [1.30, 1.74]> 10%1 study (1/-)100.0 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.